NovaBay Pharmaceuticals, Inc. (NBY)
| Market Cap | 37.37M |
| Revenue (ttm) | 9.75M |
| Net Income (ttm) | -12.80M |
| Shares Out | 40.04M |
| EPS (ttm) | -0.41 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 8 |
| Last Price | $0.919 |
| Previous Close | $0.920 |
| Change ($) | -0.001 |
| Change (%) | -0.09% |
| Day's Open | 0.944 |
| Day's Range | 0.900 - 0.950 |
| Day's Volume | 847,127 |
| 52-Week Range | 0.240 - 1.940 |
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay Pharmaceuticals (NYSE American: NBY), a pharmaceutical company focusing on commercializing Avenova® for the eye care market and CelleRx® Clinical R...
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $NBY #Avenova--NovaBay announces Avenova and CelleRx Clinical Reset to be available in brick-and-mortar stores.
EMERYVILLE, Calif.--(BUSINESS WIRE)-- #Avenova--NovaBay Pharmaceuticals announces its proprietary hypochlorous acid solution has received EPA approval for SARS-CoV-2 kill claim.
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay Pharmaceuticals Expands Avenova's Geographic Reach to Australia with New Exclusive Distribution Agreement
NovaBay Pharmaceuticals, Inc. (NBY) CEO Justin Hall on Q3 2020 Results - Earnings Call Transcript
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and nine months ended September 30, 2020 and provides a busines...
EMERYVILLE, Calif.--(BUSINESS WIRE)-- #CelleRx--NovaBay Launches CelleRx Clinical Reset and enters the beauty market
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $NBY #Avenova--NovaBay Pharmaceuticals to announce third quarter 2020 financial results on November 12
EMERYVILLE, Calif.--(BUSINESS WIRE)-- #Avenova--NovaBay regains compliance with NYSE American listing standards
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces expanded Avenova® consumer marketing programs designed to generate greater awareness of its a...
EMERYVILLE, Calif.--(BUSINESS WIRE)-- #Avenova--NovaBay® Pharmaceuticals, Inc.
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc.
NovaBay Pharmaceuticals, Inc. (NYSE: NBY) shares are trading higher after the company announced the launch of its Avenova Facial Sanitizer on Walmart Inc.
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay expands Avenova's online distribution to include Walmart.com
NovaBay Pharmaceuticals, Inc. (NBY) CEO Justin Hall on Q2 2020 Results - Earnings Call Transcript
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay reports second quarter 2020 financial results.
While penny stocks carry a high degree of risk, they could be a good place to look for value in today's market for investors that are willing to make short-term trades. These seven have potent...
EMERYVILLE, Calif.--(BUSINESS WIRE)-- #Avenova--NovaBay Pharmaceuticals to Hold Second Quarter 2020 Conference Call on August 6
NovaBay Pharmaceuticals, Inc. (NBY) CEO Justin Hall on Q1 2020 Results - Earnings Call Transcript
NovaBay Pharmaceuticals, Inc. (NBY) CEO Justin Hall on Q4 2019 Results - Earnings Call Transcript
NovaBay Pharmaceuticals, Inc. (NBY) CEO Justin Hall on Q3 2019 Results - Earnings Call Transcript
NovaBay Pharmaceuticals' (NBY) CEO Justin Hall on Q2 2019 Results - Earnings Call Transcript
NovaBay Pharmaceuticals (NYSE: NBY) shares are trading higher after the company said its plan of compliance was accepted by the New York Stock Exchange.
The 875-percent rally that propelled NovaBay Pharmaceuticals, Inc. (NYSE: NBY) shares from under 50 cents to over $3 Monday came on news of the micro-cap biotech making its Avenova eyecare pro...
NovaBay Pharmaceuticals Inc.'s stock NBY, +484.91% has blasted off to a more-than 6-fold gain in extremely active Monday afternoon trading, after the specialty pharmaceutical company said its ...
NovaBay Pharmaceuticals Inc. (NYSE: NBY) shares absolutely exploded on Monday after the company announced that its eye care treatment would be readily available on Amazon.
Shares of nano-cap biopharmaceutical company NovaBay Pharmaceuticals, Inc. (NYSE: NBY) skyrocketed 220 percent Monday morning after the company inked an agreement to sell its eye care product ...
Shares of NovaBay Pharmaceuticals Inc. nearly doubled in active premarket trade Monday, after the biopharmaceutical company said its Avenova eye-care product is now available without a prescri...
NovaBay Pharmaceuticals, Inc (NBY) CEO Justin Hall on Q1 2019 Results - Earnings Call Transcript
NovaBay Pharmaceuticals, Inc (NBY) CEO Justin Hall on Q4 2018 Results - Earnings Call Transcript
About NBY
NovaBay Pharmaceuticals, a biopharmaceutical company, develops and commercializes non-antibiotic anti-infective products to address therapeutic needs of the anti-infective market in the United States and internationally. The company offers Avenova, a solution for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye, including the eyelid; CelleRx for the aesthetic dermatology market; and NeutroPhase for the wound care market. It also develops auriclosene, a synthetic molecule for use against bact... [Read more...]
| Industry Biotechnology | IPO Date Oct 26, 2007 |
| CEO Justin Hall | Employees 26 |
| Stock Exchange NYSEAMERICAN | Ticker Symbol NBY |
Financial Performance
In 2019, NBY's revenue was $6.60 million, a decrease of -47.24% compared to the previous year's $12.51 million. Losses were -$9.66 million, 47.6% more than in 2018.
Analyst Forecasts
According to 2 analysts, the average rating for NBY stock is "Strong Buy." The 12-month stock price forecast is 2.63, which is an increase of 186.06% from the latest price.